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Abstract
Background: Resistance to contemporary broad-spectrum β-lactams, mediated by extended-
spectrum  β-lactamases (ESBL), is an increasing problem worldwide. Many of the emerging
antimicrobial resistance problems o f  t h i s  d e c a d e  h a v e  b e e n  c h aracterized by difficulty in the
recognition of resistance in the laboratory, particularly by rapid susceptibility test methods. The
plasmid-encoded ESBL represent such a resistance phenomenon that is difficult to recognize.
We compared Dio-Sensimedia-ES (DSM-ES; Diomed, Istanbul, Turkey) and Mueller-Hinton (MH)
agar in the double-disk synergy test (DDST) as a novel rapid system for detecting ESBL directly
from bacterial culture.
Methods:  Sixty ESBL-producing Klebsiella pneumoniae isolates cultured from blood (30),
endotracheal aspirates (20), urine (5) and pus (5), as well as 40 Escherichia coli isolates cultured from
endotracheal aspirates (15), urine (10), blood (8) and pus (7) were studied. Isolates positive for
ESBL by the combined disk tests were tested with the DDST using MH and DSM-ES agar to detect
ESBL-mediated resistance in K. pneumoniae and E. coli. DSM-ES agar was also used to determine the
susceptibility of Enterobacteriaceae and staphylococci.
Results: Among 60 ESBL-producing K. pneumoniae isolates, 59 (98.3%) were identified as ESBL-
positive by the DDST using MH, and 58 (96.6%), using DSM-ES agar. Of 40 ESBL-producing E. coli
isolates, 38 (95%) were ESBL-positive by the DDST on MH agar, and 37 (92.5%), on DSM-ES agar.
The average incubation period required for ESBL detection by the DDST on DSM-ES agar was 4
hours.
Conclusions: Since the DDST results were available within 4 hours when DSM-ES agar was used,
the use of this media may significantly lower the length of hospital stay, the total cost for patient
care and even the mortality rate by fascilitating early treatment against ESBL-producing organisms.
Background
Microbial resistance through extended-spectrum β-lacta-
mases (ESBL) was first reported in Europe, and subse-
quently in the United States. Today this resistance
mechanism has been recognized globally [1–6]. Many
clinical microbiology laboratories have problems to
detect ESBL-mediated resistance. Controversy exists
regarding the clinical importance of such resistance, the
choice of optimal laboratory methods to detect it, and sur-
veillance of ESBL-producing organisms. Failure to detect
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ESBL-mediated resistance has contributed to uncontrolled
spread of ESBL-producing organisms and related treat-
ment failures.
Among the genera of Enterobacteriaceae, ESBL are most
commonly produced by Klebsiella spp. and Escherichia coli
[7]. In addition, these enzymes have been isolated from
other Gram-negative bacilli including Pseudomonas aerugi-
nosa and Acinetobacter spp. [8]. Most ESBL are mutants of
TEM and SHV ß-lactamase types [9,10]. Unlike these par-
ent enzymes, ESBL hydrolyse penicillins and oxyimino-
aminothiazolyl cephalosporins including cefuroxime,
ceftriaxone, ceftizoxime, ceftazidime, cefpirome,
cefepime, but not cephamycins [10–13].
The ESBL-producing Gram-negative bacilli possess genes
encoding more than one type of the ESBL and enzymes
that are responsible for resistance to other antibiotics such
as aminoglycosides and fluoroquinolones that are active
against Gram-negative bacilli [14,15]. The emergence of
multidrug resistance in these virulent pathogens has sig-
nificantly hampered the efforts to devise effective empiric
or directed antibiotic treatment regimens [16].
ESBL-mediated resistance may be determined by several
laboratory methods, including the combined disk meth-
ods (Oxoid "Combination disks" and Mast "MAST DD"),
the double-disk synergy test (DDST), the three-dimen-
sional agar test, the investigational Vitek ESBL cards
(bioMérieux, Hazelwood, Mo., USA), and the ε-test ESBL
strip (AB Biodisk, Solna, Sweden; Cambridge Diagnostic
Services, Cambridge, UK) [17–19].
In our study, we report a novel rapid system for detecting
the presence of ESBL directly from microbiological cul-
tures. DSM (Diomed, Istanbul, Turkey) enables observa-
tion of the inhibition zones within 4 hours by changing
its color in response to the metabolic activity of growing
bacteria, even before the bacterial layer has had an oppor-
tunity to grow. DSM is an antibacterial susceptibility test-
ing agar media, which is poured in Petri dishes and used
to determine susceptibility to antibacterials by the disk
diffusion method. The use of this medium in disk diffu-
sion technique is analogous to an improved, chromogenic
version of the Kirby-Bauer disk diffusion method.
Methods
Bacterial strains and culture media
Sixty ESBL-producing K. pneumoniae isolates cultured
from blood (30), endotracheal aspirates (20), urine (5),
and pus (5) as well as 40 E. coli isolates cultured from
endotracheal aspirates (15), urine (10), blood (8), and
pus (7) were studied. The isolates were non-repetitive. All
isolates were cultured from patients hospitalized in an
intensive care unit at Istanbul Faculty of Medicine, Istan-
bul University from January 2000 through December
2001. Identification of the isolates was performed by API
20E (bioMérieux, Hazelwood, Mo., USA). E. coli ATCC
25922 and K. pneumoniae K6 (ATCC 700603) were used as
reference strains.
Screening and confirmatory tests to detect ESBL-mediated
resistance were performed according to the National
Committee for Clinical Laboratory Standards criteria [20].
Modified criteria, i.e., a diameter of <22 mm for ceftazi-
dime; <25 mm, for ceftriaxone; and <27 mm, for cefotax-
ime or aztreonam were used for interpretation of Kirby-
Bauer disk zone diameters. In this study, a combination of
ceftazidime (30 µg) and clavulanic acid (10 µg) was used.
Zones around K. pneumoniae or E. coli colonies, which
were larger than that around the disk containing ceftazi-
dime-clavulanic acid, were deemed to indicate ESBL-posi-
tivity.
DMS-ES agar was also used to determine susceptibility of
Enterobacteriaceae and staphylococci. This media changes
its color from red to yellow as bacteria grow and red circu-
lar inhibition zones forms around disks containing the
antibacterial agent. All isolates that were positive for ESBL
by the combined disk tests were tested with the DDST on
Mueller-Hinton (MH) and DSM-ES agar to detect ESBL-
mediated resistance. E. coli ATCC 25922 and K. pneumo-
niae ATCC 13883 were used as negative controls.
Double-disk synergy test
The detection of ESBL-mediated resistance by the DDST
was performed according to a published protocol [11,12].
Bacterial suspensions were prepared from overnight cul-
tures of clinical isolates to produce a turbidity of a 0.5
McFarland standard. These suspensions were then spread
on the surface of MH and DSM-ES agar plates as in the
Kirby-Bauer disk diffusion technique. Antibiotic suscepti-
bility disks containing amoxicillin (20 µg) plus clavu-
lanate (10 µg) were placed on the centre of Petri dishes
containing the two different media. Ceftazidime (30 µg),
ceftriaxone (30 µg), cefpodoxime (10 µg), aztreonam (30
µg), cefotaxime (30 µg) disks were placed 25–30 mm
apart circularly around the co-amoxiclav disk. The MH
agar plates were incubated for 24 hours at 35°C. DSM-ES
agar that is originally red, changed its color to yellow as
bacterial culture grew (Fig. 1). DSM-ES agar plates were
incubated at 35°C until red inhibition zones became
apparent. Red inhibition zones around disks containing
antibacterials were visually observed and measured.
When the disk containing co-amoxiclav extended to any
of the other antibiotic disk inhibition zones, ESBL pro-
duction was inferred [11,12] (Fig. 2).BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/22
Page 3 of 6
(page number not for citation purposes)
Evaluation of the susceptibilities by two methods
Determination of ESBL production using was done by
using both DSM-ES and Mueller-Hinton agar. The results
of the DDST using the two media were compared.
All the test results were read and interpreted by one of the
authors [AAC], who was blinded to the results of micro-
biological typing.
Results
Among 60 ESBL-producing K. pneumoniae isolates, 59
(98.3%) were identified as ESBL-positive by the DDST on
MH agar; and 58 (96.6%), on DSM-ES agar (Table 1). The
average incubation period required for detecting ESBL-
mediated resistance when using DSM-ES agar was as short
as 4 hours.
Red circle inhibition zone around the disk on the left, and at the top Figure 1
Red circle inhibition zone around the disk on the left, and at the top. Disks: centre, amoxycillin+clavulanate 20 + 10 µg; right, 
cefepime 30 µg; left, aztreonam 30 µg; top, ceftazidime 30 µg; bottom, ceftriaxone 30 µg.BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/22
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Detection of ESBL production by the double disk test on DSM-ES agar Figure 2
Detection of ESBL production by the double disk test on DSM-ES agar. Disks: centre, amoxycillin+clavulanate 20 + 10 µg; right, 
cefepime 30 µg; left, ceftriaxone 30 µg; top, ceftazidime 30 µg; bottom, aztreonam 30 µg.
Table 1: Percentage of ESBL-positive Isolates as Determined by DDST either on MH or DSM-ES Agar
Combined Disk Test DDST on MH Agar DDST on DSM-ES Agar
K. pneumoniae (n = 60) 60 59 (98.3%) 58 (96.6%)
E. coli (n = 40) 40 38 (95%) 37(92.5%)BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/22
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Of 40 ESBL-producing E. coli isolates, 38 (95%) were pos-
itive on MH agar; 37 (92.5%), on DSM-ES agar (Table 1).
The average incubation period required for detecting
ESBL-mediated resistance by the DDST on DSM-ES agar
was 4 hours.
Discussion
ESBL are encoded on conjugative plasmids, tranposons or
integrons. These mobile genetic elements are readily
spread under selective antibiotic pressure [21]. Increased
clinical use of antibiotics, access to antibiotics without a
doctor's prescription in many countries, international
travel, and uncontrolled use of antibiotics in the environ-
ment and by meat-producers have led to an increase in
antibiotic resistance in many bacterial species [22]. Early
determination of ESBL-mediated resistance is clinically
crucial in cases like meningitis, bacteremia and sepsis in
order to start appropriate therapies as early as possible.
Even in less emergent situations, early determination of
antibacterial susceptibility is important to select the
appropriate treatment regimens and increase the success
rate of the therapy, lower the rate of side-effects of antibi-
otics, and decrease health-care costs.
Clinical and financial benefits of early determination of
antibacterial susceptibility have been shown in many
studies [23]. Barenfarger et al [23] reported that early
reporting of antibacterial susceptibility tests resulted in a
decrease in the length of hospital stay by 2.0 days and in
the average total cost per patient by US$ 2395. Doern et al
[24] reported a saving of US$ 4194 per patient in addition
to a statistically significant lower mortality rate when a
rapid antibiotic susceptibility test was used.
The detection of ESBL-mediated resistance in Gram-nega-
tive bacilli is one of the major problems in a clinical
microbiology laboratory [13]. The techniques recom-
mended for this purpose by the NCCLS guidelines is not
easily performed in routine clinical practice. Several auto-
mated systems such as Vitek (bioMerieux, NC, USA) and
MicroScan Walkaway (Diamond Diagnostics, MA, USA)
aimed to provide early results have recently become avail-
able and approved by the Food and Drug Administration.
Another commercial assay used for ESBL detection, the ε-
test is available from two manufacturers (AB Biodisk,
Solna, Sweden; and Cambridge Diagnostic Services, Cam-
bridge, UK). These commercial assay kits have a sensitivity
of >90% to detect ESBL-mediated resistance.
Published data on the accuracy and the speed of such sys-
tems are limited. McGregor et al [25] evaluated MicroScan
to test susceptibility of Gram-negative bacteria, and found
major and minor discrepancies in 2% and 8% of the sam-
ples assayed, respectively, as compared to a standard test.
When testing susceptibility of Gram-positive bacteria,
major and minor discrepancies occured in 1% and 7% of
the samples assayed, respectively. In this study 93% of the
results were available within 7 hours. Ling et al [26] com-
pared the Vitek 2 AST-No. 12 cards and the broth micro-
dilution method to test susceptibility of 228 isolates,
including various members of the Enterobacteriaceae, Pseu-
domonas aeruginosa and other Gram-negative bacteria.
They reported major discrepancies (resistant by the Vitek
2 system but sensitive by the broth microdilution
method) in 0.5 %, and very major discrepancies (sensitive
by the Vitek 2 system but resistant by the broth microdilu-
tion method) in 0.4% of the tests.
A phase-three trial compared the disk diffusion method,
which is recommended by the NCCLS guidelines, with an
automated growth-monitoring system (Vitek ESBL). In
this trial, the two methods were found to be comparable
in both sensitivity (98% for disk diffusion vs. 99.7% for
Vitek ESBL) and specificity (99.4% for disk diffusion and
100% for Vitek ESBL) [18]. Cormican et al. compared the
ε-test with the disk diffusion method. ε-test was found to
be more sensitive than the disk diffusion method (100%
vs. 87%), whereas both methods were comparable in their
specificity [27].
Although the DDST detected K. pneumoniae more fre-
quently than E. coli, this test was equally efficent to detect
ESBL-mediated resistance in both species. The average
incubation period required to detect ESBL-mediated
resistance in both species was approximately 4 hours. In
this study, the DDST on DSM-ES agar proved to be a reli-
able, rapid and cost-effective test for detecting of ESBL in
K. pneumoniae and E. coli. Since the DDST results can be
obtained within 4 to 6 hours when DSM-ES agar is used,
the use of this media may significantly lower the length of
hospital stay, the total cost for patient care and even the
mortality rate by fascilitating early treatment.
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